NVAX.US
id: 912
Novavax (NVAX) $47M Shareholder Settlement
It is still possible to file a late claim. The court will decide whether to accept late claims or not.
D. Maryland
Court8:21-cv-02910
Case number11 May 2021
Class period Start19 Oct 2021
Class period End18 May 2024
Claim deadlineNovavax (NVAX) agreed to settle $47M with investors to end claims over the vaccine approval issues.
Case Status
Accepting Late Claims
Alleged Offence
Misleading Statements,
Failure to Disclose,
Omissions
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
1.24
Filing date
12 November 2021
Lead Plaintiff Deadline
11 January 2022
Plaintiffs
Jeffrey A. Gabbert, Nuggehalli Balmukund Nandkumar, David Truong
Attorneys
Cohen Milstein Sellers & Toll PLLC (Washington, DC), Labaton Sucharow LLP (New York, NY), Pomerantz LLP (New York, NY), Portnoy Law Firm (Los Angeles, CA)
Defendants
Stanley C. Erck, Gregory F. Covino, John J. Trizzino, Gregory M. Glenn
Judge
Hon. Theodore D. Chuang
Administrator
Strategic Claims Services
Court hearing date
23 May 2024
Exclusion deadline
02 May 2024
Objection deadline
02 May 2024
Class wide damages
$2,351,400,000
Trades matching type
FIFO
+$47,000,000
Cash Settlement Amount